Gexval, Inc.

GEXVal Inc. March 14, 2025 GEXVal Inc. (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) is pleased to announce that Chief Technology Officer (CTO) Yusuke Nakayama, Ph.D., will present innovative applications of its proprietary next-generation drug discovery platform "RePhaIND"(1) at the 145th Annual Meeting of the Pharmaceutical Society of Japan(2) - Promoting the Pharmaceutical Ecosystem: Creating Future Innovation through Cross-disciplinary Collaboration, to be held in Fukuoka, Japan from March 26 to 29, 2025. GEXVal pioneers the application of cutting-edge artificial intelligence (AI) technologies, specifically Graph Attention Network (GAT) and Graph Attention Autoencoder (GATE) (3), to the field of drug discovery. We are challenging the status quo through innovative technology development and clinical advancement that explores new possibilities and brings a paradigm shift to conventional drug discovery processes. RePhaIND®(2) is a proprietary data-driven drug discovery platform developed by GEXVal that creates new value in pharmaceutical development. By leveraging innovative AI technology to understand complex relationships in pharmaceutical research—such as interactions between drug candidate compounds and their target molecules, and disease mechanisms—as "connections" for AI learning, this platform enables the creation of novel pharmaceutical solutions that would be difficult to identify through conventional methods. RePhaIND®accelerates the creation of new drug discovery projects and brings a paradigm shift to the drug discovery process. In this presentation, we will report on our innovative analytical methods and case studies utilizing Graph Neural Networks (GNNs)(3). Key Points of the Presentation: The presentation will cover three main aspects of our research: "With the advancement of AI technology, drug discovery research is entering a new phase," says Dr. Nakayama. "We are honored to have this opportunity to present at this annual meeting where researchers from both academia and the pharmaceutical industry gather. We look forward to discussing the possibilities of AI, in particular the applications of GNNs(3) in drug discovery and sharing both the technical innovation and practical value of our RePhaIND®(2) platform with experts in the field." GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology (RePhaIND®(2)), we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families. **Presentation Details** Conference The 145th Annual Meeting of the Pharmaceutical Society of Japan URL The 145th Annual Meeting of the Pharmaceutical Society of Japan Date March 28, 2025, 16:45-18:09 Venue Fukuoka International Congress Center, Fukuoka, Japan / Room 8 (409+410 [4F]) Session Information and Computational Chemistry (Session will be conducted in Japanese) Chairs Associate Professor Noriyuki Yamaotsu (Kitasato University) Associate Professor Hiroaki Saito (Hokuriku University) Abstract No 28-08-pm22 Title Data-driven drug discovery using Graph Neural Networks: Identification of therapeutic candidates for COVID-19 1) About the Pharmaceutical Society of Japan Established in 1880, the Pharmaceutical Society of Japan is the country's oldest academic society. It represents Japan's pharmaceutical research community with approximately 15,000 members from academic institutions and pharmaceutical industry. For details: https://www.pharm.or.jp 2) About RePhaIND®：Revolutionary Pharmacoinformatics to Find IND (Investigational New Drug) Powered by RePhaIND® - EMPOWER・ACCELERATE・REVOLUTIONIZE Drug Discovery RePhaIND® is GEXVal's proprietary AI-driven drug discovery platform with three key features: EMPOWER: Discover hidden relationships between drug candidates and diseases ACCELERATE: Dramatically improve efficiency compared to conventional methods REVOLUTIONIZE: Enable new approaches to unmet medical needs, particularly in rare diseases, bringing a paradigm shift to the drug discovery process RePhaIND® is a registered trademark of GEXVal Inc. in Japan, China, Hong Kong, Korea, Australia, Europe, UK, and US and a trademark in other countries and regions. 3) About Graph Neural Networks (GNNs) Graph Neural Networks (GNNs) are AI technologies that learn patterns from various "connections" in data. In particular, Graph Attention Network (GAT) is widely used in everyday services such as social media recommendations and logistics route optimization. Notably, Graph Attention Autoencoder (GATE), which GEXVal pioneered in drug discovery, has previously been limited to specific applications in life sciences, such as protein structure prediction. By innovatively applying GATE technology to the entire drug discovery process, GEXVal enables the discovery of novel therapeutic candidates that would otherwise remain unidentified through conventional methods. For further information: Head of Corporate office Atsushi Sugizaki info@gexval.com

GEXVal Inc. February 21, 2025 GEXVal Inc. (President & CEO Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) announces that it has raised JPY 50 million through a third-party allotment of shares from a business corporation as part of its Series C extension round (hereinafter “this capital increase”). With this funding, our company has successfully reached our Series C target, completing the round with JPY 910 million. This funding will accelerate the clinical development and enhance the value of GXV-001(1) while strengthening our business operations. GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology (RePhaIND®(2)), we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families. (1) About GXV-001: GXV-001 has completed Phase I clinical trials and Proof of Mechanism* studies through our wholly owned subsidiary, GEXVal AU Pty Ltd. We are currently preparing for Phase II clinical trials as a clinical development program for neurological disorders. * Proof of Mechanism (POM): In clinical trials, this refers to "proof of mechanism of action," which verifies that the drug exerts pharmacological effects on the intended target molecule and induces physiological responses. (2) About RePhaIND®: Powered by RePhaIND® - EMPOWER・ACCELERATE・REVOLUTIONIZE Drug Discovery RePhaIND® is GEXVal's proprietary AI-driven drug discovery platform powered by Graph Attention Autoencoding (GATE)-a state-of-the-art neural network architecture that analyzes complex biological relationships in a multimodal approach. This innovative platform offers three key features: EMPOWER: Discover hidden relationships between drug candidates and diseases ACCELERATE: Dramatically improve efficiency compared to conventional methods　 REVOLUTIONIZE: Enable new approaches to unmet medical needs, particularly in rare diseases, bringing a paradigm shift to the drug discovery process For further information: Head of Corporate office Atsushi Sugizaki info@gexval.com

GEXVal Inc. February 14, 2025 GEXVal Inc. (President & CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, "GEXVal") is pleased to announce that it has been selected to receive research funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) (1) for research into non-motor symptoms of Parkinson's disease (PD)(2) . The news release from MJFF can be viewed here: URL: https://www.michaeljfox.org/grant/investigation-novel-therapeutic-approach-non-motor-symptoms-parkinsons-disease The research grant of approximately USD 1.3 million (approximately JPY 200 million) comes from MJFF's Parkinson's Disease Therapeutics Pipeline Program. The program will support preclinical research using multiple Parkinson's disease animal models. Dr. Kohei Shimada, our Chief Scientific Officer, stated, "Non-motor symptoms of Parkinson’s disease represent a significant unmet medical needs. We are grateful for this opportunity to advance our research program through MJFF's support." GEXVal strives to ensure Treatment Reaches the Unreached, focusing on rare diseases and underserved medical conditions. By leveraging its proprietary AI-driven pharmacoinformatics technology (RePhaIND®(3)), the company illuminates paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver innovative, life-changing medicines that bring new hope to patients and their families. Notes: 1）About MJFF: The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is the world’s largest nonprofit funder of Parkinson’s research. For information about the foundation and its program, please visit: https://www.michaeljfox.org/what-we-fund 2）About Parkinson’s disease: Parkinson's disease is a progressive neurodegenerative disorder characterized by motor symptoms such as bradykinesia, muscle rigidity, tremors, and postural instability, as well as non-motor symptoms including sleep disorders, autonomic dysfunction, depression, anxiety, and cognitive impairment, which can significantly impact daily activities. In Japan, Parkinson's disease is designated as an intractable disease by the Ministry of Health, Labour and Welfare (MHLW), making patients eligible for medical expense support and assistance programs. For more information: -MJFF Parkinson’s Disease Information: https://www.michaeljfox.org/parkinsons-101 -MHLW designated intractable diseases website [Japanese only] : https://www.mhlw.go.jp/stf/newpage_36011.html?utm_source=chatgpt.com 3）RePhaIND® is a registered trademark of GEXVal Inc. For further information: Head of Corporate office Atsushi Sugizaki info@gexval.com